Abstract. As one of the most serious types of primary bone tumor, osteosarcoma (OSA) features metastatic lesions, and resistance to chemotherapy is common. The underlying mechanisms of these characteristics may account for the failure of treatments and the poor prognosis of patients with OSA. It has been reported that inhibition of Cyr61 suppresses OSA cell proliferation as it represents a target of statins. In addition to cystein-rich protein 61 (Cyr61) and nephroblastoma o�ere�-and nephroblastoma o�ere�-pression, connecti�e tissue growth factor (CTGF) is a member of the CCN family and may therefore e�hibit effects on human OSA cells similar to those of Cyr61. In the current study, acridine orange/ethidium bromide staining were used to determine the rate of apoptosis. The present study demonstrated that small interfering RNA-mediated silencing of CTGF promoted cell death and suppressed OSA cell migration and in�asion, as indicated by wound healing and Transwell assays, while lenti�irus-mediated o�ere�pression of CTGF re�ersed these effects. Furthermore, a colorimetric caspase assay demonstrated that CTGF knockdown enhanced the efficacy of chemotherapeutic drugs. The results of the present study pro�ided a no�el molecular target which may be utilized for the treatment of metastatic OSA.
Introduction
Osteosarcoma (OSA) is globally one of the most common types of primary bone tumor and is predominantly obser�ed in children and adolescents (<20 years old) (1) . Patients with localized disease have a five-year recurrence-free survival rate of 80%; howe�er, the prognosis of OSA is poor in metastatic osteosarcoma. In spite of OSA occurring in any type of bone in the body, the metaphyseal (acti�ely growing) regions of the distal femur, pro�imal tibia and pro�imal humerus are the most frequent origins of the primary tumor and the sites with the highest probability of metastasis are the lungs and distant bones (2) .
It has been reported that se�eral genes are able to regulate cell proliferation and differentiation; these genes carry numerous mutations associated with significant neoplasmic abnormalities in OSA (3) (4) (5) (6) (7) (8) (9) . Of note, mutations in tumor suppressor genes, including p53, MDM2 and riboblastoma protein ha�e been reported to ha�e major roles in the tumorigenesis of OSA (3, 4) . OSA is also associated with the aberrant e�pression of certain transcription factors e�pressed in bones, including c-fos, whose o�ere�pression has been shown to result in OSA in the bones of mice (5) , as well as osteoblast differentiation factor osteri� (6, 7) . In OSA cell lines, Run�2 was found to be downregulated or dysfunctional (8) , and in high-grade pediatric OSA, genomic aberrations in the Twist ha�e been reported (9) .
Resistance to con�entional chemotherapy is one of the characteristics of metastatic OSA and represents a considerable obstacle for its clinical treatment (10) . Howe�er, only a small number of genes, including HES1 (11) (12) (13) and Ezrin (10) ha�e been implicated in the progression and metastasis of OSA.
It has been reported that statins e�ert anti-tumoral effects on OSA cells (13) (14) (15) . Cystein-rich protein 61 (Cyr61), a member of the Cyr61/connecti�e tissue growth factor (CTGF)/nephroblastoma o�ere�pressed (NOV) (CCN) family of secreted proteins, was among the factors downregulated by statins. This CCN protein family comprises Cyr61, CTGF, NOV and Wnt-induced secreted proteins (WISP)1, -2 and -3 (16) . As a member of the CCN family, CTGF was hypothesized ha�e effects on osteocarcinoma similar to those of statins. The present study therefore assessed the effects of CTGF knockdown or lenti�irus-mediated o�ere�pression of CTGF as well as statin treatment on the biological properties of OSA cells.
Materials and methods
Cell lines and culture. The SaOS2, U2OS, MG63, OHS4 and CAL72 cell lines (American Type Culture Collection, Manassas, VA, USA) were cultured in Dulbecco's modified Eagle's medium (Invitrogen; Thermo Fisher Scientific, Waltham, MA, USA) supplemented with 10% fetal calf serum (FCS; Thermo Fisher Scientific) at 37˚C in a humidified atmosphere containing 5% CO 2 in air.
RNA extraction and reverse-transcription quantitative polymerase chain reaction (RT-qPCR).
TRIzol reagent (In�itrogen; Thermo Fisher Scientific) was used to isolate RNA according to the manufacturer's instructions, which was stored at -20˚C. cDNA was synthesized using 3 µg RNA, which was denaturated and re�erse-transcribed by using 300 U Moloney murine leukemia �irus re�erse transcriptase, 15 mg oligo dT primers and 1 mM deo�ynucleoside triphosphate (dNTP) (Promega, Madison, WI, USA) in a total �olume of 30 µl. SYBR Green Master Mi� kit (ABGen, Courtaboeuf, France) was used for qPCR. A total of 0.5 mM of each primer (In�itrogen; Thermo Fisher Scientific) was used with sequences as follows: Human CTGF, forward 5'-CAG GCT AGA GAA GCA GAG CC-3' and re�erse 5'-GTA ATG GCA GGC ACA GGT CT-3'; β-actin, forward 5'-CTC CAT CCT GGC CTC GCT GT-3' and re�erse 5'-GCT GTC ACC TTC ACC GTT CC-3'. Thermocycling was conducted using the ABI 7500 (Applied Biosystems; Thermo Fisher Scientific) and the cycling conditions were as follows: Initial denaturation at 95˚C for 15 min, followed by 40 cycles of 20 sec at 95˚C, 15 sec at 58˚C and 15 sec at 72˚C, and final extension at 72˚C for 7 min. The 2 -ΔΔCt method was used to determine the relati�e quantities of RNA.
Plasmid transduction. In order to in�estigate the role of CTGF in OSA, cell lines were transduced with lenti�iral �ectors (LV) encoding either the full-length sequence (LV-CTGF) or a specific short hairpin (sh)RNA (sh-CTGF). The full-length CTGF ORF (1047 base pairs; GenBank accession number, CR541759.1) was amplified from the pFLAG-CMV2-CTGF plasmid (Invitrogen; Thermo Fisher Scientific). The primer sequences were as follows: Forward, 5'-TACTGGCGGCGGTATACCCG-3' and re�erse, 5'-TGCCATGTCTCCGTACAT-3'. The PCR product was inserted into the e�pression �ector pcDNA3.1/myc-His(-)B-3X FLAG-IRES-hrGFP, deri�ed from pcDNATM3.1/myc-His(-)B (In�itrogen; Thermo Fisher Scientific). Cell transduction was performed using Lipofectamine 2000 (Invitrogen; Thermo Fisher Scientific) according to the manufacturer's instructions.
Proliferation assay. A bromodeo�yuridine (BrdU) incorporation assay was used to quantify cell replication. A pre�iously described procedure was used in the present study (17) . In brief, cells were cultured for 24 h in the presence of increasing concentrations of bisphosphonates (10 -9 -10 -4 M) and labeled with BrdU for the last 6 h (kit purchased from GE Healthcare Life Sciences, Roosendaal, The Netherlands).
Detection of apoptosis and necrosis. Double staining with ethidium bromide and acridine orange was performed to �isualize and quantify the number of �iable cells (green nuclei), apoptotic cells (nuclei condensed and colored orange), and necrotic cells (red nuclei). In briefly, 2 µl dye mixture (100 µg/ml acridine orange and 100 µg/ml ethidium bromide) was added to 20 µl cell suspension and immediately e�amined with the 40X oil immersion objecti�e using a Leitz DMRB fluorescence microscope (green/red filter; 100 W lamp; Leica Microsystems GmbH, Wetzlar, Germany) equipped with a photometrics CCD camera and the Logikon image analysis system (Numeris Benelux SA, Ath, Belgium). Several fields, randomly chosen, were digitized and 600-800 nuclei for each sample were counted and scored. Results were e�pressed as the relati�e percentages of �iable, apoptotic and necrotic cells to the total number of cells scored.
Caspase activity. Effector caspase acti�ity was performed as pre�iously described (14, 15) . In brief, cells were treated with 10 mM ator�astatin (Adooq BioScience LLC, Ir�ine, CA, USA) or the sol�ent for 24 h then the caspase acti�ity was determined. Cellular e�tracts (50 µg) were incubated with 0.2 mM acetyl-Asp-Glu-Val-Asp-p-nitroanilide (caspases-3, -6 and -7; Enzo Life Sciences, Inc., Farmingdale, NY, USA), Ac-LEHD-pNA (caspase-9; Enzo Life Sciences, Inc.) or Ac-IETD-pNA (caspase-8; Enzo Life Sciences, Inc.) as the substrates for the previously reported times (14, 15) at 37˚C in the presence or the absence of the specific caspase inhibitors Ac-DEVD-CHO, Ac-LEHD-CHO and Ac-IETD-CHO (10 µM). The specific activity (nmol of pNA/min/mg protein) was e�pressed as treated o�er control ratios.
Migration and invasion assays.
A wound-healing assay was performed following the manufacturer's instructions (ibidi GmbH, Martinsried, Germany). A Transwell migration and in�asion assay as performed as described pre�iously (14) . In brief, the cells (50,000 cells/insert) were incubated 2 h with or without statin and/or z-VAD-fmk prior to seeding into the inserts and incubation for a further 22 h. The cells that did not migrate through the filter were removed from the upper surface of the membrane using cotton-tipped swabs. The cells migrated to the underside were fixed in 3.7% paraformaldehyde in phosphate-buffered saline (PBS) at 4˚C and stained with crystal �iolet (Amresco, Solon, OH, USA). The membranes were then cut from the insert and obser�ed under a microscope (A�ioplan 2 Imaging Mot Microscope System; Zeiss, Oberkochen, Germany). Five fields were randomly selected and counted and each assay was performed in duplicate.
Western blot analysis. A protocol of a pre�ious study was used for the preparation of cell lysates (14) In brief, the proteins (30 µg) were resol�ed using 12% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE; Protogel, Atlanta, GA, USA) and transferred onto poly�inylidene difluoride nitrocellulose membranes (EMD Millipore, Billerica, MA, USA). The filters were incubated at room temperature for 2 h in 50 mm Tris-HCl (pH 7.4), 150 mm NaCl, 0.1% (�/�) Tween 20, 0.5% (w/�) bo�ine serum albumin (TBST/BSA) and then overnight at 4˚C on a shaker with the rabbit monoclonal anti-GAPDH (ab181602) and anti-CTGF (ab6992) antibodies (1:1,000 in TBST/BSA; Abcam, Cambridge, UK). The membranes were washed twice with TBST and incubated for 2 h with the horseradish pero�idase-conjugated secondary antibody (1:20,000 in TBST/BSA). Following the final washes, the signals were visualized with Enhanced Chemiluminescence Western Blotting Detection Reagent (GE Healthcare Life Sciences) and autoradiographic film (X-Omat AR; Kodak, Rochester, NY, USA). Densitometric analysis using ImageQuant software was performed following digital scanning (Odyssey ® Fc; Agfa-Ge�aert, Mortsel, Belgium).
Immunoblot analysis. A protocol of a pre�ious study was used for the preparation of cell lysates (14, 15) . Incubation with rabbit monoclonal anti-GAPDH (ab181602; 1:200) and rabbit polyclonal anti-CTGF (ab6992; 1:200) antibodies was conducted at 4˚C overnight. Cell e�tracts were collected in 2X loading lysis buffer [50 mM Tris-HCl (pH 6.8), 2% SDS, 10% 2-mercaptoethanol, 10% glycerol and protease inhibitor cocktail; Sigma-Aldrich, St. Louis, MO, USA]. The total cellular proteins were separated using 8% SDS-PAGE and trans-ferred to Hybond-C nitrocellulose membranes (GE Healthcare Life Sciences, Chalfont, UK). Subsequent to blocking with PBS containing 5% BSA or nonfat milk, the membranes were incubated with the primary antibodies, followed by incubation with IRDye 800CW or 680RD secondary antibodies (1:10,000; LI-COR Biosciences, Lincoln, NE, USA). The protein bands were detected using the Odyssey Infrared Imaging System (Li-COR Biosciences).
Statistical analysis.
Values are e�pressed as the mean ± standard de�iation. Two-factor analysis of �ariance was used to compare �alues between groups, using SPSS software, �ersion 19.0 (IBM SPSS, Armonk, NY, USA). P<0.05 was considered to indicate a statistically significant difference between �alues.
Results

CTGF expression is reduced by atorvastatin (statin) in OSA cells.
RT-qPCR analysis of CTGF was performed in the SaOS2, U2OS, CAL72, MG63 and OHS4 human OSA cell lines, re�ealing that CTGF mRNA was e�pressed in all cell lines, particularly in SaOS2 cells (Fig. 1A) . Furthermore, the effect of statin treatment on the e�pression of CTGF was assessed in the OSA cell lines. CTGF mRNA e�pression in the panel of OSA cell lines was markedly decreased following treatment with statin (10 mM) (P<0.05 �s. untreated) (Fig. 1B) .
In addition, the effect of statin (10 mM) on the protein le�els of CTGF in the panel of cell lines was assessed by immunoblot analysis, re�ealing that the protein le�els of CTGF were decreased following statin (Fig. 1C) . Collecti�ely, these results indicated that statin treatment led to the downregulation of CTGF in human OSA cells. As the SaOS2 and U2OS cell lines e�pressed the highest and lowest le�els of CTGF, respecti�ely, they were selected to be used in the subsequent e�periments.
CTGF expression does not affect OSA cell proliferation.
A BrdU incorporation assay were used to determine the proliferati�e rates of transduced and parental cells, re�ealing that these were not affected by plasmid transduction (Fig. 2A) . The results therefore indicated that CTGF had no significant effects on OSA-cell proliferation in human cell lines.
Evasion of apoptosis by OSA cells is dependent on CTGF expression.
The present study in�estigated the effects of CTGF on OSA cell death. As shown in Fig. 2B , apoptotic and necrotic indices of sh-CTGF-transduced cells were higher than those of parental cells. By contrast, LV-CTGF-transduced cells displayed lower apoptotic and necrotic indices compared with those of parental cells. Furthermore, it was re�ealed that sh-CTGF-transduced cells e�hibited increased caspase acti�ity and an ele�ated Ba�/Bcl2 ratio compared with those of parental cells. By contrast, caspase acti�ity and the Ba�/Bcl2 ratio were reduced in CTGF-o�ere�pressing OSA cells compared with those in parental cells ( Fig. 2C and D) . These results indicated that CTGF e�pression was associated with the e�asion of apoptosis by OSA cells. The dose-dependent cytoto�ic effects of do�orubicin, cisplatin and methotre�ate on OSA cell �iability are utilized for the chemotherapeutic treatment of OSA (14) . The present study revealed that CTGF silencing significantly enhanced the caspase acti�ity in SaOS2 cells following treatment with do�orubicin, cisplatin or methotre�ate, whereas LV-CTGF 
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slighly decreased caspase le�els compared with those in nati�e SaOS2 cells treated with the chemotherapeutics (Fig. 3A-C) . It is therefore concluded that silencing of CTGF enhanced the efficacy of chemotherapeutic drugs against OSA.
Cell migration and invasion are dependent on CTGF expression in vitro.
The present study further in�estigated the in�asi�eness and migratory potential of transduced OSA cell lines, which represent the main characteristics of OSA progression and the de�elopment of metastasis. The results showed that CTGF silencing inhibited wound healing in sh-CTGF-transduced cells compared with that in parental cells, while CTGF o�er-e�pression enhanced wound healing (Fig. 4A ). In addition, CTGF o�ere�pression enhanced the migratory potential in a Transwell assay (Fig. 4B) . The obser�ed inhibition of the migratory potential by statin was not able to be rescued by o�ere�pression of CTGF (Fig. 4C) . Furthermore, a Transwell assay using Matrigel-coated inserts re�ealed that silencing of CTGF inhibited the in�asi�e capacity of OSA cells, while cell in�asi�eness was promoted by CTGF o�ere�pression (Fig. 4D) . All of these results implied that CTGF had positi�e effects on cell migration and in�asi�eness in vitro, whereas in�asion and migration were reduced in CTGF-silenced OSA cells. It can be concluded that CTGF e�pression is associated with the aggressi�eness and metastatic potential of OSA cells.
Discussion
Conser�ed cysteine residues co�alently bound to isoprenoids can be post-translationlly modified by prenylation, which is essential for the pro-tumorigenic acti�ity of certain guanosine triphosphatases, including Ras and Rho-like proteins (18, 19) . Synthetic bisphosphonates with inhibitory acti�ities on geranylgeranyltransferase type and farnesyltransferase can be utilized as anti-cancer drugs which partly block prenylation through inhibition of farnesyl pyrophosphate (FPP) synthase acti�ity; this approach is a no�el therapeutic strategy for se�eral cancer types, including OSA and bone metastases (20) (21) (22) (23) (24) (25) . Statins act as hypocholesterolemic agents with inhibitory effects on the acti�ity of 3-hydro�y-3-methylglutaryl-coenzyme A reductase (26) and represent another class of drug which acts through depleting downstream isoprenoid residues, including such as geranylgeranylpyrophosphate or FPP. Pre�ious studies on OSA reported that statins not only induced apoptosis but also reduced cell migration and in�asion, and potentiated the effects of chemotherapeutic agents (13) (14) (15) . Howe�er, the anti-cancer efficacy of statins in vivo remains to be clarified. Pre�ious clinical studies indicated that statins, apart from e�hibiting anti-cancer effects, may also be associated with an increased risk for the de�elopment of cancer de novo (27) (28) (29) .
These conflicting results indicate that the understanding of the mechanisms of action of statins is required to be e�panded and refined, and that novel targets for cancer therapy require to be disco�ered.
Pre�ious studies reported that Cyr61, which encodes a secreted protein known to modulate tumor de�elopment and progression, was downregulated by statins (30) (31) (32) and that CTGF is also among the molecular targets of statins (33, 34) . CTGF is a matricellular protein of the CCN family of e�tra-cellular matri�-associated heparin-binding proteins, which comprises Cyr61, CTGF, NOV and WISP1-3 (35) (36) (37) . CTGF has important roles in numerous biological processes, including cell adhesion, migration, proliferation, angiogenesis, skeletal de�elopment and tissue wound repair, and is critically in�ol�ed in fibrotic disease and se�eral types of cancer (33,34,38) . Members of the CCN protein family ha�e similar domains, The present study enhanced or silenced the e�pression of CTGF in human OSA cells to determine the role of CTGF in OSA de�elopment and progression. A BrdU incorporation assay did not reveal any significant effects of CTGF on the proliferation of human OSA cell lines. By contrast, CTGF silencing slightly increased OSA cell death and enhanced the anti-neoplasic and pro-apoptotic effects of the chemotherapeutics do�orubicin, cisplatin and methotre�ate, which may represent a no�el strategy to enhance the efficacy of OSA treatments. A positive combinatory effect of statins with chemotherapeutic drugs in OSA or other cancer types has been indicated by pre�ious studies (13, (39) (40) (41) (42) . The present study focused on CTGF e�pres-sion in OSA cells, independent of the presence of statins. As silencing of CTGF enhanced the anti-tumoral effects chemotherapeutic drugs, it was indicated that CTGF knockdown may reduce the resistance of OSA cells to chemotherapy.
OSA bears the characteristics of rapid and frequent de�elop-ment of metastatic lesions. In vitro e�periments performed in the present study demonstrated that the migratory and in�asi�e capacities of human OSA cells were reduced by CTGF silencing, whereas CTGF o�ere�pression led to an increase in cell migration and in�asion. By contrast, pre�ious studies reported that silencing or inhibition of CTGF reduced the motility and in�asi�eness of breast and prostate cancer cells (43, 44) . Due to this discrepancy, the roles of CCN family proteins, particularly CTGF, in OSA require further study. In OSA cell lines, No� was reported to be e�pressed at �ariable le�els (45) and may be associated with poor prognosis and an increased risk of de�eloping metastases (46) . The predicti�e �alue of CTGF e�pression le�els with regard to the outcome and progression of human OSA requires to be in�estigated in future studies analyzing CTGF e�pression in primary and metastatic tumors.
In conclusion, the results of the present study re�ealed that OSA cell in�asion and migration was regulated by CTGF in vitro. CTGF was indicated to ha�e a critical role in the genesis and progression of human OSA, and to be in�ol�ed in the e�asion of apoptosis, aggressi�eness and metastasis formation of OSA. Targeting of CTGF may be a strategy to enhance the efficacy of chemotherapeutics in the treatment of OSA as well as to reduce the aggressi�eness of OSA cells.
